Terms: = Pancreatic cancer AND GATA1, ERYF1, P15976, 2623, ENSG00000102145, NFE1, GF1 AND Treatment
5 results:
1. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
2. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Serda M; Malarz K; Mrozek-Wilczkiewicz A; Wojtyniak M; MusioĊ R; Curley SA
Sci Rep; 2020 Jan; 10(1):260. PubMed ID: 31937861
[TBL] [Abstract] [Full Text] [Related]
3. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells.
Kisfalvi K; Guha S; Rozengurt E
J Cell Physiol; 2005 Mar; 202(3):880-90. PubMed ID: 15389644
[TBL] [Abstract] [Full Text] [Related]
4. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract] [Full Text] [Related]
5. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1.
Guha S; Rey O; Rozengurt E
Cancer Res; 2002 Mar; 62(6):1632-40. PubMed ID: 11912133
[TBL] [Abstract] [Full Text] [Related]
